ERS: European Respiratory Society

Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.

Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital, discusses therapies and management guidelines for patients with interstitial lung disease (ILD).

Io Hui, PhD, researcher at The University of Edinburgh, discusses challenges to implementing artificial intelligence in respiratory care.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF).

Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Speakers at the 2024 meeting of ERS—The European Respiratory Society Congress share their favorite parts of the conference.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, shares the latest clinical discoveries from the BOREAS trial on type 2 inflammation in patients with chronic obstructive pulmonary disease (COPD).

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

Sulthiame demonstrated significant reductions in respiratory pauses and improvements in oxygen levels during sleep, offering hope for patients with obstructive sleep apnea who cannot use continuous positive airway pressure machines.

Eva Otter, president of Pulmonary Hypertension Association Europe, discusses the significance of shared decision-making for patients with pulmonary arterial hypertension.

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for severe asthma and dupilumab for pediatric asthma.

New findings highlight the potential role of artificial intelligence in supporting health care professionals, but thorough testing is needed before its integration into everyday clinical practice.

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, shares findings from the FLAME trial on blood eosinophil changes in patients with chronic obstructive pulmonary disorder.

Wanda Phipatanakul, MD, MS, professor of pediatrics at Harvard Medical School and director of the Clinical Research Center at Boston Children's Hospital, discusses some of the most significant health disparities impacting respiratory care.

Io Hui, PhD, researcher at The University of Edinburgh, discusses how artificial intelligence (AI) is being applied in respiratory care for both clinicians and patients.

A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).

There are general risk factors for patients with rheumatic disease developing interstitial lung disease, but there are also disease-specific risk factors depending on which rheumatic disease they have, explained Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital.

Speakers at the European Respiratory Society Congress 2024 highlighted the potential of artificial intelligence (AI) in transforming respiratory health care, while also raising important ethical concerns related to autonomy, equity, transparency, and sustainability.

The European Respiratory Society (ERS) Congress 2024 will delve into the balance between human expertise and the growing role of artificial intelligence (AI) in respiratory medicine.

Martin Kolb, MD, PhD, professor of medicine at McMaster University, previews key topics to be presented at this year's European Respiratory Society (ERS) Congress.

Increasing air pollution and climate change have an impact on respiratory health and mortality, explained speakers in 2 sessions on the environment and respiratory diseases at the European Respiratory Society International Congress 2021.

Two posters reviewed impairment after COVID-19 infection and the use of pulmonary rehabilitation to address the symptoms.

Gefapixant successfully improved quality-of-life and reduced cough severity for patients with chronic cough vs placebo, according to 2 posters.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

Outcome inconsistency in randomized controlled trials for pneumonia could create issues for interpreting data and compiling research going forward, said Alexander Mathioudakis, MD, MRCP, at the European Respiratory Society annual meeting.

Adolescents and adults are affected differently by vaping and have different health concerns, according to Ilona Jaspers, PhD, director of toxicology and the deputy director of the Center for Environmental Medicine, Asthma, and Lung Biology at the Gillings School of Global Public Health at the University of North Carolina.

Dual bronchodilators have been shown to broadly improve symptoms and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD).